AstraZeneca, Pfizer Team With Quebec Government In Drug R&D Effort
This article was originally published in The Pink Sheet Daily
Executive Summary
The Neomed Institute, which will start by advancing three pain molecules contributed by AstraZeneca, will work to advance early-stage candidates through proof-of-concept and then license out the programs.